



Docket No.: 0760-0343PUS1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Masateru YAMADA et al.

Application No.: 10/523,689

Confirmation No.: 8519

Filed: August 11, 2005

Art Unit: 1656

For: REMEDY OR PREVENTIVE FOR KIDNEY  
DISEASE AND METHOD OF DIAGNOSING  
KIDNEY DISEASE

---

Examiner: S. Swope

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE AND AMENDMENT**

MS Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

On March 29, 2006 the U.S. Patent and Trademark Office mailed to Applicant's representative a Notification of Defective Response.

Enclosed is an Amendment responding to the Notification of Defective Response.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Application No.: 10/523,689

Docket No.: 0760-0343PUS1

Dated: April 19, 2006

Respectfully submitted,

By 

Andrew D. Meikle

Registration No.: 32,868

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

Attachment: Copy of Notification of Defective Response



**BOX SEQUENCE**  
**PATENT**  
**0760-0343PUS1**

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Masateru YAMADA et al. Conf.: 8519  
Appl. No.: 10/523,689 Group: 1656  
Filed: February 3, 2005 Examiner: S. Swope  
For: REMEDY OR PREVENTIVE FOR KIDNEY DISEASE  
AND METHOD OF DIAGNOSING KIDNEY  
DISEASE

AMENDMENT

Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Defective Response mailed March 29, 2006, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

This Reply includes:

- Amendments** to the Specification begin on page 2 of this paper.
- Amendments** to the Sequence Listing begin on page 13 of this paper.
- Remarks/Arguments** begin on page 14 of this paper.
- An **Appendix** including the paper and CRF disk copy of the Sequence Listing is attached following page 14 of this paper.